Information  X 
Enter a valid email address

Parkmead Group (The) (PMG)


Thursday 26 September, 2019

Parkmead Group (The)

Completion of Acquisition and Total Voting Rights

RNS Number : 6986N
Parkmead Group (The) PLC
26 September 2019

26 September 2019


The Parkmead Group plc

("Parkmead", "the Company" or "the Group")



Completion of Acquisition and Total Voting Rights



Further to the announcement on 30 August 2019, The Parkmead Group plc is pleased to announce all outstanding conditions in connection with the acquisition of Pitreadie Farm Limited ("Pitreadie") have now been satisfied.  


In accordance with the terms of the transaction, 9,645,669 new ordinary shares of 1.5 pence each ("Consideration Shares") will be admitted to trading on AIM today, 26 September 2019 ("Admission").


Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 108,574,829 Ordinary Shares, with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 108,574,829.


The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.


For enquiries please contact:


The Parkmead Group plc

+44 (0) 1224 622200

Tom Cross (Executive Chairman)

Ryan Stroulger (Chief Financial Officer)      

Arden Partners plc

(Financial Adviser, NOMAD and Corporate Broker to Parkmead)

+44 (0) 20 7614 5900

Corporate Finance: Ciaran Walsh

Equity Sales: Aimée Kerslake


Instinctif Partners Limited (PR Adviser to


David Simonson

Sarah Hourahane

Dinara Shikhametova




+44 (0) 20 7457 2020




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t